# High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

> **NCT02284490** · PHASE2 · UNKNOWN · sponsor: **Rongjie Tao** · enrollment: 25 (estimated)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT02284490
- **Lead sponsor:** Rongjie Tao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2016-10
- **Final completion:** 2017-11
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2014-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284490, "High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02284490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*